Alkem Laboratories Cuts Tofe Range Prices by Half for Rheumatoid Arthritis & Ulcerative Colitis Relief

In a move to make Rheumatoid arthritis treatment more affordable, Alkem Labs has slashed the prices of its popular brand, Tofe, by more than 50 percent.

Tofe tablets are available in two strengths, Tofe 5mg contains Tofacitinib citrate 5mg and Tofe ER 11mg comes with Tofacitinib citrate 11mg Extended Release.

To enhance therapy accessibility and compliance among rheumatoid arthritis patients, Tofe 5mg, previously priced at INR 42.9 per tablet, will now be available at INR 19/- per tablet. Similarly, Tofe ER 11mg, previously available at INR 64.5 per tablet, now comes at INR 32/- per tab.

Tofe, which contains Tofacitinib citrate, is approved by DCGI for the treatment of Rheumatoid arthritis, Psoriatic Arthritis, and Ulcerative Colitis.

In Rheumatoid Arthritis, Tofacitinib may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

Tofacitinib is a second-generation selective Janus kinase (JAK) inhibitor targeting the JAK1 enzyme, involved in adaptive and innate immune responses in immune-mediated inflammatory diseases (IMIDs).

“Alkem remains dedicated to advancing healthcare solutions that positively impact patient's lives. This price reduction for Tofe reflects a pivotal step in providing access and relief to millions of Rheumatoid Arthritis patients”.